These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25366054)

  • 1. [Anti-HIV drugs].
    Koibuchi T
    Uirusu; 2013; 63(2):199-208. PubMed ID: 25366054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 antiretroviral drug therapy.
    Arts EJ; Hazuda DJ
    Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reverse transcriptase inhibitors, protease inhibitors].
    Tachikawa N
    Nihon Rinsho; 2012 Apr; 70(4):579-95. PubMed ID: 22568138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modern HIV treatment].
    Lehmann C; Malin J; Suárez I; Fätkenheuer G
    Internist (Berl); 2019 Apr; 60(4):411-419. PubMed ID: 30778612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer antiretroviral agents and how to use them.
    Kim HH; Daar ES
    Curr HIV/AIDS Rep; 2009 May; 6(2):55-62. PubMed ID: 19358775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.
    Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
    Torres HA; Rallapalli V; Saxena A; Granwehr BP; Viola GM; Ariza-Heredia E; Adachi JA; Chemaly RF; Marfatia R; Jiang Y; Mahale P; Kyvernitakis A; Fanale MA; Mulanovich V
    Clin Microbiol Infect; 2014 Oct; 20(10):O672-9. PubMed ID: 24529214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging anti-HIV drugs.
    De Clercq E
    Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiretroviral drugs.
    Gulick RM
    Clin Microbiol Infect; 2003 Mar; 9(3):186-93. PubMed ID: 12667250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.